Thinking about a small cap growth play, I would ideally like to see:

- a clear proprietary advantage based on IP (patents and know-how being better than patents alone)

- technology that is demonstrably superior to incumbent alternatives

- technology that has been proven in the field over some years, as opposed to being “nearly ready”.

- very large & directly addressable global markets

- endorsement of technology by industry thought leaders

- a reasonably capital-light operational model

- high gross margins

- little to no debt & sufficient cash for the medium term

- directors holding 10% + of shares on issue

- extensive ongoing research to broaden the product suite/applications being conducted at scale and at someone else’s expense

- a share price that has been hampered by phenomenon that are likely to prove temporary

- clear operational/financial step changes being implemented

- No operational gap between what has been promised and what has been delivered

- despite all of the above, a lower EV/REV than peers

I think that Osteopore ticks every single one of these boxes.

But why take my word for it ? Have a read:

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02633224-6A1137097?access_token=83ff96335c2d45a094df02a206a39ff4

I'm not going to venture a valuation except to say that I hold in real life and that it's north of eleven cents.